A federal appeals court has rejected a drug manufacturer’s appeal and affirmed a judge’s order that Actavis PLC keep distributing its widely used Alzheimer’s medication until after its patent expires this summer.
New York Attorney General Eric Schneiderman had sought the order and called the Court of Appeals ruling a victory for consumers. His office says the drug Namenda should remain on shelves 30 days after the patent expires July 11.
He alleged anti-trust and state law violations by Actavis in an effort to push patients to its new patented drug and avoid losses from cheaper generics.
Dublin-based Actavis says its new drug Namenda XR is better and demand is growing. It’s taken once daily, not twice daily.
Full content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI